SMART Study in Real World

A. \*\*Prospective Study: \*\* In this cohort, the long-term safety and efficacy of the approved msRDN system will be evaluated in patients with drug-resistant hypertension or patients who are intolerant to drug therapy and, in either case, need to reduce antihypertensive medications. Study Period and Timeline (for A. Prospective Cohort)\*\* Subjects included in this post-market, real-world study will be followed for at least three years after msRDN procedure. The regarding clinical parameters will be taken at baseline and at each follow-up as below: * Visit 0: Baseline/Screening Period * Visit 1: msRDN procedure (Day 0) * Visit 2: 1 Month Post-msRDN (30 ± 7 days) * Visit 3: 3 Months Post-msRDN (90 ± 14 days) * Visit 4: 6 Months Post-msRDN (180 ± 30 days) * Visit 5: 12 Months Post-msRDN (360 ± 30 days) * Visit 6: 24 Months Post-msRDN (720 ± 30 days) * Visit 7: 36 Months Post-msRDN (1080 ± 30 days) B. \*\*Retrospective Study:\*\* In this cohort, the safety and efficacy of msRDN system will be evaluated in patients with drug-resistant hypertension or patients who are intolerant to drug therapy and, in either case, need to reduce antihypertensive medications, who have been treated by msRDN procedure. \*Study Period and Timeline (for B. Retrospective Cohort) \*\* Patients who have been consented and enrolled in the study will be followed for at least three years. In this cohort, as long as a patient meets inclusion criteria of the study and at least one clinical efficacy endpoint is recorded at ≥36 months after msRDN procedure, the data from this patient will be used for statistical analysis. During 36 month study period, data will be collected at baseline and at each follow-up point per protocol as below: * Visit 1: msRDN procedure (Day 0) * Visit 2: 1 Month Post-msRDN (30 ± 14 days) * Visit 3: 3 Months Post-msRDN (90 ± 28 days) * Visit 4: 6 Months Post-msRDN (180 ± 28 days) * Visit 5: 12 Months Post-msRDN (360 ± 28 days) * Visit 6: 24 Months Post-msRDN (720 ± 28 days) * Visit 7: 36 Months Post-msRDN (1080 ± 28 days) Final Follow-Up The midpoints of two adjacent follow-ups are used as the reference to determine which follow-up point the data belong to: if data are collected before the midpoint and accounted in the early follow-up；if data are collected after the midpoint and accounted in the later follow-up.